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262 The Journal of Thoracic and Cardbjectives: In the current study we describe and characterize a novel ovine model
f biventricular hypertrophy and heart failure and evaluate the role of selected
ardiac transcription factors in the regulation of cardiac gene expression during
athologic hypertrophy in vivo. The cardiac troponin T promoter is used as a model
ene.
ethods and Results: Transient transfections of ovine cardiomyocytes in culture
how that Sp1, transcriptional enhancer factor-1, and myocyte enhancer factor-2
ctivate cardiac troponin T promoter constructs. Cotransfection of Sp3 inhibits
ardiac troponin T promoter activity and represses Sp1-mediated activation of
he cardiac troponin T promoter. By chromatin immunoprecipitation, transcrip-
ional enhancer factor-1, myocyte enhancer factor-2, NKX2.5, GATA-4, and Sp
actors bind the cardiac troponin T promoter in vivo. To assess the role of
ardiac transcription during pathologic hypertrophy, in vivo, we created surgical
orta-pulmonary shunts in utero in fetal lambs. Two weeks after spontaneous
elivery, shunted lambs showed failure to thrive, significant biventricular hy-
ertrophy, and heart failure. Shunted hearts had significant increases in myosin
nd cardiac troponin T protein expression. There was a shift in expression to the
igh-molecular-weight fetal isoforms. Transcriptional enhancer factor-1, myo-
yte enhancer factor-2, GATA-4, NKX2.5, and Sp1 transcription factor levels
ere increased in all heart chambers of shunted animals. Sp3 expression was
ecreased in shunted ventricles. Immunoprecipitated Sp3 was associated with
ignificant increases in histone acetyl transferase activity and decreases in
istone-deacetylase activity.
onclusion: The shunted neonatal lamb is a valid, novel model of pathologic
iventricular hypertrophy. During pathologic hypertrophy myocardial transactiva-
ors are upregulated while repressors are downregulated.
ardiac failure and dysfunction can result from numerous clinicopathologic
conditions including hypertension, ischemic heart disease, valvular heart
disease, cardiomyopathy, and congenital heart disease. The need for effec-
ive broad-based therapy for patients with heart failure far outweighs and has
utpaced current therapeutic strategies. Further understanding of the complex cel-
ular mechanisms that lead to heart failure may aid in the development of novel and
ffective therapies.
iovascular Surgery ● December 2006
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DVarious pathologic signals, stressors, or biomechanical
orces elicit different intracellular signaling pathways that
ltimately stimulate fetal cardiac gene expression (in chil-
ren and adults) and pathologic hypertrophy, an early mile-
tone in heart failure.1,2 Although numerous biomechanica
orces and pathologic conditions can result in myocardial
ysfunction, it is hypothesized that there is a final common
athway in which transcriptional alterations in sarcomeric
ene expression, common to many forms of pathologic
ypertrophy (concentric, eccentric), result in contractile
ysfunction of the heart. Thus, contractile dysfunction of
he heart can be viewed as a transcriptional disorder.3,4
Transcription factors are nuclear proteins that bind pro-
oter regulatory elements to activate or repress gene ex-
ression. The combinatorial interactions between transcrip-
ion factors and promoter elements that are required for the
egulation of cardiac gene expression during normal cardiac
evelopment probably operate during pathologic cardiac
emodeling and hypertrophy. NKX2.5, myocyte enhancer
actor 2 (MEF2), HAND, and GATA transcription factors
ave been implicated in transcriptional control, pattern for-
ation, and segmental control of cardiac development5-8
sing the cardiac troponin T (cTnT) promoter as a model
ene, we have shown that transcriptional enhancer factor-1
TEF-1), MEF2, and Sp family of transcription factors also
ontribute to the developmental regulation of cardiac gene
xpression in avian embryonic cardiomyocytes.9,10 These
yocardial transcription factors, which are important for
ormal growth, development, and maintenance of the car-
iac phenotype, may also be implicated during induction of
etal genes and the upregulation of constitutive genes that is
een with pathophysiologic hypertrophy.2,11
Recent interest in “transcriptional disorders of the heart”
as also implicated cardiac histone acetylation in the devel-
pment of pathologic cardiac hypertrophy and heart failure.
istone acetyl transferases (HATs) are believed to acetylate
istone proteins, relax chromatin, and expose “prohypertro-
hic” genes for activation by cardiogenic transcription fac-
ors.12,13 Histone deacetylases (HDAC classes I and II) h
Abbreviations and Acronyms
ADP  adenosine diphosphate
ChIP  chromatin immunoprecipitation
cTnT  cardiac troponin T
HAT  histone acetyl transferase
HDAC histone deacetylase
MEF2 myocyte enhancer factor 2
PAR  poly(adenosine diphosphate ribose)
PARP  poly(adenosine diphosphate ribose)
polymerase
TEF-1  transcriptional enhancer factor-1lso been implicated in regulation of myocardial gene ex- w
The Journal of Thoracicression and cardiac hypertrophy.4,12,14 Class I HDAC
ay act as prohypertrophic agonists.15-17 Thus, isoform-
pecific inhibitors of class I HDACs and/or cardiac-specific
ATs may have an important and specific inhibitory effect
n the development of pathologic cardiac hypertrophy, con-
ractile dysfunction, and heart failure.15-19
Recently, Kee and colleagues15 have shown that inhib-
ion of histone deacetylation blocks cardiac hypertrophy
nduced by angiotensin II infusion and aortic banding. Sim-
larly, Kong and colleagues20 reported that suppression o
lass I and II HDACs blunts pressure-overload cardiac
ypertrophy. Suppression of ventricular growth was well
olerated in terms of both clinical outcome and cardiac
erformance measures. Interstitial fibrosis was diminished
n hearts treated with HDAC inhibitors, and collagen syn-
hesis in isolated cardiac fibroblasts was suppressed. There
as no evidence of cell death or apoptosis. Systolic function
n the setting of blunted hypertrophic growth was preserved,
s shown by echocardiography and hemodynamic data. The
ypertrophy-associated switch of adult and fetal sarcomeric
soforms was attenuated, which likely contributed to the
bserved preservation of systolic function in HDAC
nhibitor-treated hearts. Both these studies suggest that
DAC inhibition is a viable therapeutic strategy that holds
romise in the treatment of pressure load-induced heart
isease. The effects of HDAC inhibition on volume-loaded
eart dysfunction are not known.
The aims of the current study are (1) to biochemically and
orphologically characterize a clinically relevant model of
athologic hypertrophy and congestive heart failure and (2) to
etermine the changes in expression levels and posttransla-
ional modifications of selected cardiac transcription factors. In
tero placement of aorta–pulmonary arterial shunts has been
eported as a model of postnatal pulmonary hypertension with
ncreased pulmonary blood flow in lambs21 and is used in th
tudy as a model of pathologic cardiac hypertrophy. Surgically
reated aorta-pulmonary shunts in fetal lambs produced left
entricular volume overload and right ventricular pressure
verload, leading to altered contractile protein gene expression,
iventricular hypertrophy, and congestive heart failure. In the
hunted lamb model, pathologic cardiac remodeling and dele-
erious cardiac gene expression occurred in association with
hanges in the levels and modification states of cardiac-specific
ranscription factors (GATA-4, DTEF-1, Sp1, Sp3, and
KX2.5). Furthermore, we show that, functionally, TEF-1,
EF2, and Sp1 factors, which bind the cTnT promoter within
he context of chromatin, transactivate the cTnT promoter in
vine cardiomyocytes, implicating them as important regula-
ors of the pathologic hypertrophic process.
aterials and Methods
eagents
edia, serum, enzymes, reagents, and materials for tissue culture
ere purchased from the Cell Culture facility at the University of
and Cardiovascular Surgery ● Volume 132, Number 6 1263
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Dalifornia, San Francisco. Oligonucleotides were purchased from
peron Technologies Inc (Alameda, Calif) or Invitrogen (Carlsbad,
alif).
lasmids and Constructs: Tissue Culture, Cell
ransfections, and Reporter Gene Assays
he promoter/reporter constructs used in this study consist of
68 nucleotides of the chicken cTnT promoter upstream of the
ranscription initiation site (Gallus domesticus cardiac isoform
f troponin T [TNT] gene, exon 1, and promoter sequence.
CCESSION# M5790). Luciferase reporter constructs were cre-
ted and subcloned into the plasmid pGL2 (Promega, Madison
is), as previously described.9
Hearts were harvested from neonatal lambs and cardiomyo-
yte cultures established by standard techniques.10 The differ-
ntiation state of cultured cardiomyocytes was determined by
ight microscopy, presence of beating cardiomyocytes, immu-
ocytochemistry for MF20, and Western blotting for myosins,
TnT, GATA-4, MEF2, and NKX2.5. Plasmid constructs were
ransfected according to the manufacturer’s protocol (Effectene
ransfection kit; Qiagen, Valencia, Calif) with minor modifi-
ations.9 Reporter gene activity was determined with the D
uciferase reporter assay (DLR-Promega, Madison, Wis). Fire-
y light intensity was read on a Luminometer TD-20/20, DLR
eady (Turner Designs Instrument, Sunnyvale, Calif). Cotrans-
ection with 20 ng phRL-TK reporter was used to standardize
or transfection variability. Cotransfection efficiency of Sp,
EF2, and DTEF-1 expression constructs was verified with
SV--galactosidase (Promega, Madison Wis) and/or pAAV-
FP staining. Reporter gene activity was expressed as mean 
tandard deviation. Statistical comparisons were performed by
aired t tests.
uclear Extracts
ardiac muscle was harvested from 2-week-old lambs (control and
hunted) at 4°C. Nuclear extracts were prepared by standard meth-
ds (Active Motif, Inc, Carlsbad, Calif).
estern Blot Analysis and Densitometry
otal protein concentration was quantitated with the Bio-Rad DC
rotein assay kit (Bio-Rad Laboratories, Hercules, Calif). An equal
mount of protein was loaded in each lane for Western blots:
odium dodecylsulfate–polyacrylamide gel electrophoresis was
sed to separate nuclear proteins (10 g) on a 10% gel and
ollowed by transfer to a polyvinylidene difluoride membrane
Amersham Biosciences, GE Healthcare Bio-Sciences Corp, Pis-
ataway, NJ). Membranes were then blocked and incubated with
ntibody as previously described.9 Reactive bands were visualize
ith the SuperSignal West Femto Maximum Sensitivity Substrate
it (Pierce, Rockford, Ill) and Kodak 440CF image station
Kodak, New Haven, Conn). The image was selected and analyzed
ith the public domain program NIH Image, and band intensity
as quantified. Parallel sodium dodecylsulfate gels and immuno-
lots of -actin and glyceraldehyde-3-phosphate dehydrogenase
ontrols were performed to verify sample integrity and loaded
uantity. m
264 The Journal of Thoracic and Cardiovascular Surgery ● Decurgical Preparations and Care: Ewes
regnant, mixed-breed Western ewes (135-140 days’ gestation;
erm  145 days) were operated on under sterile conditions.
hrough a left lateral fetal thoracotomy, an 8.0-mm polytetrafluo-
oethylene vascular graft (2-mm length; W. L. Gore & Associates,
nc, Flagstaff, Ariz) was sewn between the ascending aorta and
ain pulmonary artery. All lambs were spontaneously delivered
nd were instrumented as previously described.21
eart Tissue Preparation
hole heart and chamber-specific weights were measured in all
hunted and control specimens. Samples of right atrium, right
entricle, left atrium, left ventricle, and ventricular septum were
xcised, weighed, and used to make fresh nuclear preparations.
hole tissue and excess nuclear preparations were snap-frozen in
iquid nitrogen. Samples were stored at 70°C until used for
nalysis.
etermination of DNA Content
NA content was determined by standard methods (Genomic
NA mini-prep; Bay Gene Inc, San Francisco, Calif). Values were
ormalized to gram of cardiac muscle.
tatistical Analysis
omparisons between shunt and age-matched controls were made
y an unpaired t test.
All protocols and procedures were approved by the Committee
n Animal Research of the University of California, San Fran-
isco. All animals were put to death by appropriate methods as
escribed in the National Institutes of Health Guidelines for the
are and Use of Laboratory Animals.
esults
n Utero Placement of Aorta–Pulmonary Shunts
esults in Growth Failure, Four-chamber
ardiomegaly, and Biventricular Hypertrophy
hunted lambs showed clinical evidence of failure to thrive.
ompared with control animals, shunted lambs were tachy-
neic and demonstrated less activity and lower tolerance to
tress after 1 week of age. By 2 weeks of age, shunted lambs
ad significantly slower weight gain than controls. The
earts of shunted lambs were significantly larger than those
f controls (Figure 1, Table 1, and Figure E1). All
hambers showed substantial increases in mass without
ignificant increases in DNA content, suggesting that hy-
ertrophy and not hyperplasia was the predominant stress
esponse. The left ventricle was dilated and showed evi-
ence of eccentric hypertrophy, while the right ventricle
as predominantly thick-walled with evidence of concen-
ric hypertrophy.
emodynamics of 2-week-old Shunted Lambs
able 1 summarizes the hemodynamics of shunted ve
ontrol lambs at 2 weeks of age. Shunted animals had
ignificantly higher mean pulmonary artery pressures with a
ean pulmonary/systemic flow ratio of 2.9:1. Left and right
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Dtrial pressures were significantly higher in shunted
nimals.
arcomeric Protein and Myocardial Transcription
actor Levels Are Altered During Pathophysiologic
hunting in the Neonatal Ovine Heart
estern blots of shunted (n  5) and control (n  5) hearts
ere analyzed by band densitometry. The hearts of 2-week-
ld shunted lambs showed significant increases in myosin
nd cTnT expression (Figure 2 and Figure 3, A and B).
etal, high-molecular-weight isoforms of cTnT were up-
egulated, consistent with the activation of a pathologic
ypertrophic program (Figure 2). The increase in sa
eric protein expression and associated fetal isoforms was
een in all four chambers. Associated with the increase in
arcomeric proteins, a variety of cardiac transcription fac-
ors known to govern cardiac gene expression during em-
igure 1. Gross pathology of shunted hearts at 2 weeks of age.
eft panel, Photograph of shunted heart. Right panel, Photograph
f control heart.
ABLE 1. General hemodynamics in 2-week-old lambs
Control
lambs
Shunted
lambs
ean arterial blood pressure (mm Hg) 65 7 55  7
ulmonary arterial pressure (mm Hg) 15 2 22  4*
eft pulmonary blood flow
(mL · kg1 · min1)
60  21 157 28*
eart rate (beats/min) 171 24 174 25
eft atrial pressure (mm Hg) 3 1.7 7 3.4*
ight atrial pressure (mm Hg) 2.2 1.4 4.8 3.1*
ulmonary/systemic blood flow 1.00 2.91 01*
ight ventricular weight (g) 11 2 21  5*
eft ventricular weight (g) 19 4 31  7*
otal cardiac weight (g) 49 6 80  8*
alues are means  SD; n  6 shunted lambs and 7 twin or age-matched
ontrols. *P  .05 shunt versus control lambs; weight comparisons wereBerformed for 5 control and 5 shunted lambs.
The Journal of Thoracicryogenesis, growth, and development were upregulated
Figures 2 and 3). TEF-1 factors, which regulate mu
ene promoters (eg, cTnT, - and -myosin heavy chains,
ropomyosins, -acetylcholine receptor, and -actin genes)
hrough muscle CAT sites, were significantly upregulated in
he right side of the heart (Figure 3, C). There was a tren
o increased expression in the left atrium and left ventricle.
igure 2. Characteristic Western blot of sarcomeric proteins and
elected transcription factors in 2-week-old control and shunted
ambs. Antibody used for Western blot analysis is listed on left. MF20
antimyosin) and cTnT levels are increased in shunted animals,
onsistent with the hypertrophy and increased mass seen on gross
athologic examination. Fetal/embryonic isoforms of cTnT are ex-
ressed in the hypertrophied, shunted hearts. There are associated
ncreases in DTEF-1, MEF2 (not shown), GATA4, NKX2.5, and Sp1
evels and concomitant decreases in Sp3 levels within the cardiac
hambers (see Figure 5). -actin and glyceraldehyde-3-phosphate
ehydrogenase (GAPDH) control proteins are comparable in shunted
nd control specimens. RA, Right atrium; RV, right ventricle; LA, left
trium; LV, left ventricle; Sept, interventricular septal muscle; MW
kDa), molecular weight in kilo-Daltons.oth GATA-4 and NKX2.5 levels were significantly in-
and Cardiovascular Surgery ● Volume 132, Number 6 1265
CH
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Dreased in all four chambers (Figure 3, D and E). The
agnitude of the increase in NKX2.5 levels, although sta-
istically significant, was small (Figure 3, E). Densitometric
nalysis of Sp factor expression showed that Sp1, a tran-
criptional activator of cardiac promoters, was increased in
ll four chambers; Sp3, a transcriptional repressor of cTnT
romoter constructs, was significantly downregulated dur-
ng pathologic hypertrophy.
Immunohistochemistry was performed to determine the
ell type and compartment within which transcription factors
ere localized (Figures E2, E3, and E4). Previous studies have
hown that MEF2, GATA-4, and NKX2.5 predictably localize
o the nucleus of myocytes and act as transcriptional activa-
ors.5-7, 22-25 TEF-1, Sp1, and Sp3 are expressed within 
yocyte population of the ovine heart and localize to the
ucleus. By chromatin immunoprecipitation, DTEF-1,
EF2, GATA-4, NKX2.5, Sp1, Sp3, and poly(adenosine
iphosphate [ADP]-ribose) polymerase (PARP) bind the
vine cTnT promoter “in vivo,” within the context of chro-
atin (Figure E5). Furthermore, anti-PAR and pan-acetyl
ntibody immunoprecipitated chromatin from cardiomy-
cytes that yielded a positive chromatin immunoprecipi-
ation (ChIP) assay for cTnT binding, implicating that
hese epigenetic modifications (poly-ADP-ribosylation
nd acetylation) were present in the transcriptional pro-
eins that bound the cTnT promoter in vivo. Co-immu-
oprecipitation experiments with MEF2 and neonatal
ardiomyocytes confirmed that Sp factors, PARP,
KX2.5, and DTEF-1 directly interacted to potentially
orm a transcriptional complex (data not shown).
ranscriptional Effects on cTnT Promoter Activity
aving shown that selected cardiac transcription factors are
odulated during pathologic hypertrophy and bind the
TnT promoter (and are associated with epigenetic modifi-
ations of acetylation and poly-ADP-ribosylation), in vivo,
e sought to determine their transactivating effects. Expres-
ion constructs of DTEF-1A and B, MEF2C, Sp1, and Sp3
ere cotransfected with cTnT promoter constructs in pri-
ary neonatal sheep cardiomyocytes in culture (Figure
elative activity was indexed to a reporter gene driven by
hymidine kinase to control for transfection variability. Both
Figure 3. Bar graphs of densitometric analysis of
biventricular hypertrophy in neonatal lambs. Bands
of control (n  5) and shunted (n  5) neonatal lam
cardiac troponin protein expression are increased in
the right side of the heart whereas NKX 2.5, GATA-4,
cardiac chambers. A, Myosin expression detected
proteins. D, GATA-4. E, NKX2.5. F, Sp1. G, Sp3. -actin
(I) were used as controls. RA, Right atrium; RV,
interventricular septal muscle.
The Journal of Thoracicsoforms of DTEF-1, A and B, transactivated the 268cTnT
romoter approximately 3.2-fold and 3.6-fold above base-
ine, respectively (268cTnT  16  3 relative light units vs
68cTnT  DTEF1A 51  7 relative units; 268cTnT 
TEF-1B  58  6 relative units, n  5 transfections per
onstruct, P  .01). Cotransfection of MEF2C with the
68cTnT promoter construct resulted in a 4.3-fold increase
n baseline reporter gene activity (268cTnTMEF2C 70
6 relative units, n  5, P  .01.). Cotransfection of both
EF2C and DTEF-1B expression constructs produced a
.7-fold increase in reporter gene activity (92  8 relative
nits, n  5, P  .01). Sp1 acted as a transcriptional
ctivator of 268cTnT promoter constructs that were tran-
iently transfected in ovine cardiomyocytes in culture, pro-
ucing a 2.2-fold increase in baseline reporter gene activity
36  6 relative units, n  5, P  .01). Sp3 repressed
aseline 268cTnT promoter activity by over 50% and
nhibited Sp1-mediated transcriptional activation of the pro-
oter (Figure 4).
iscussion
n utero placement of aorta–pulmonary shunts produces
athologic biventricular hypertrophy and clinical congestive
eart failure in neonatal lambs. There are associated in-
reases in constitutively expressed sarcomeric proteins and
nduction of fetal isoforms of contractile proteins in all four
ardiac chambers. In this model, there is upregulation of
yocardial transcriptional activators and downregulation of
epressors. Furthermore, cardiac transcription factors also
ndergo changes in interactions with cardiac histone acety-
ating and deacetylating enzymes, as well as ADP-ribose
olymerases, each of which are potential pharmacologic
argets of PARP, HDAC, and HAT inhibitors.4,26
n Vivo Model of Pathologic Cardiac Hypertrophy
urine models of cardiac hypertrophy are favorable be-
ause the mouse is amenable to transgenic manipulation,
llowing for the identification of molecular mechanisms of
athophysiologic processes. Aortic banding or constriction
n the mouse, which has a heart rate of 500 beats/min and
hamber dimensions in the millimeter range, is a commonly
ted myocardial transcription factors during pathologic
on Western blots of myocardial specimens from hearts
ere analyzed by quantitative densitometry. Myosins and
four chambers. TEF-1 proteins are primarily increased in
p1 are upregulated and Sp3 is downregulated in all four
MF20 antibody. B, Cardiac troponin T (cTnT). C. TEF-1
nd glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
ventricle; LA, left atrium; LV, left ventricle; Septum,selec
seen
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Dsed animal model for the study of pathologic hypertrophy.
chocardiographic or hemodynamic analysis of murine
odels, although well established, requires special equip-
ent and expertise. Compared with mouse models of patho-
ogic hypertrophy, the ovine model has some advantages. It
s amenable to standard echocardiographic and catheteriza-
ion techniques and is not limited to the study of only
ressure loading of the left side of the heart, but can be used
o study other biomechanical stressors including volume
oading of the heart. Furthermore, pathologic hypertrophy
an be generated in either the left or right ventricle, or both,
hus allowing for the determination of common or asym-
Figure 4. Luciferase reporter gene activity driven by2
in primary cultures of neonatal ovine cardiomyocytes.
DTEF-1A or B, and MEF2C are cotransfected. Cotransfec
activity. Sp3 inhibits Sp1-mediated gene activation. M
activity. Horizontal axis, Cotransfected expression c
indexed to TK-driven reporter to control for transf
pcDNA4HisMax expression constructs have undetecta
omyocyte cultures shows reporter gene expression reetric transcriptional responses of either side of the heart. t
268 The Journal of Thoracic and Cardiovascular Surgery ● DecThe ovine model used in this study, that is, in utero
lacement of a large aorta-pulmonary shunt in fetal lambs,
roduces significant left-to-right shunting and increases in
ulmonary blood flow and pulmonary hypertension. The
eft ventricular myocardium is stressed by persistent and
ignificant volume loading, while the right ventricle even-
ually experiences pressure loading. This model is clinically
elevant and mimics some congenital heart defects, such as
atent ductus arteriosus, large ventricular septal defects, and
orta-pulmonary windows. Furthermore, volume loading of
he left ventricle is also clinically seen with valvular heart
isease such as aortic and mitral insufficiency. Right ven-
nT promoter constructs that are transiently transfected
line –268cTnT relative activity is increased when Sp1,
of Sp3 results in repression of baseline cTnT promoter
nd DTEF-1 have a synergistic effect on reporter gene
ructs. Vertical axis, Relative reporter gene activity
n variability. Cells alone, pGL2 basic vector, and
ctivity (not shown). Anti-luciferase staining of cardi-
ed to myocyte population.68cT
Base
tion
EF2 a
onst
ectio
ble a
strictricular pressure overload is also commonly seen clinically,
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Ds in pulmonary hypertension, tetralogy of Fallot, and pul-
onary stenosis. Last, the model mimics the surgically
reated aorta–pulmonary shunts used for the management of
ingle ventricle anomalies with inadequate pulmonary blood
ow.
The central features of the cardiomyocyte hypertrophic
esponse include increases in contractile protein content,
nduction of contractile protein isoforms, and expression of
mbryonic markers.11 The observed protein biochemica
hanges in this model are consistent with expected changes
n sarcomeric protein expression. There is an upregulation
f constitutively expressed genes (myosins), as well as
nduction of fetal contractile and noncontractile cardiac
enes (high-molecular-weight troponin isoforms and atrial
atriuretic factor/brain natriuretic peptide [data not shown]).
roto-oncogenes and other members of the immediate-early
ene programs, also known to be activated during hyper-
rophy, were not evaluated in this study, nor were regulators
f cell survival and apoptosis.11
The finding that TEF-1, NKX2.5, Sp1, and GATA fac-
ors are upregulated during the cardiac hypertrophic re-
ponse is consistent with their chromatin binding and trans-
ctivating properties. Likewise, downregulation of Sp3
uring pathologic hypertrophy is consistent with its inhibi-
ory effects on cTnT promoter activity. These data suggest
hat the increase in sarcomeric proteins and induction of
mbryonic cardiac genes seen during pathologic hypertro-
hy are preceded and regulated by increases in myocardial
ransactivators, decreases in cardiac gene repressors, and
nduction of posttranslational modifications that modulate
ranscription factor function. These data do not provide
irect evidence that TEF-1, MEF2, NKX2.5, GATA-4, and
p1 upregulation and Sp3 downregulation, in vivo, are
echanistically responsible, in part, for the changes in
arcomeric protein expression that are seen during patho-
ogic cardiac hypertrophy in the ovine model. Further stud-
es are warranted to investigate these important
echanisms.
The TEF-1 family of transcription factors has been im-
licated in muscle gene regulation.27 We have previously
loned and characterized DTEF-1, a cardiac-enriched fam-
ly member that regulates cardiac gene expression and is
xpressed in the early embryo.9,10 During volume loading o
he left ventricle and pressure loading of the right ventricle,
EF-1 polypeptides are upregulated to a greater degree in
he right side of the heart. TEF-1 upregulation during
iomechanical stress may therefore be an asymmetric,
hamber-specific response or may act as a pressure-
esponsive rather than volume-responsive transactivator.
oly-ADP-ribose polymerase, a known coactivator of
EF-1,28 has been implicated in myocardial cell hypox
schemic injury and cardiomyocyte survival. In this
odel, we have also found that DTEF-1 becomes heavily
The Journal of ThoracicDP-ribosylated (data not shown), a process amenable to
nhibition and potential target for pharmacotherapy of
eart failure.29
The Sp family of transcription factors is important in the
ssembly of the basal transcriptional machinery, potentially
cting as a central and widespread regulatory network in
athologic hypertrophy. We have previously shown that
p1 and Sp3 have counterregulatory functions in avian
yocytes.30 Although Sp3 expression is downregulat
uring pathologic hypertrophy, we have found that Sp3-
ssociated HAT activity is increased and HDAC activity is
ignificantly decreased (Figures E6 and E7). Hence, acety-
ation of Sp3 may convert it from a repressor to a transcrip-
ional activator during the induction of pathologic cardiac
ypertrophy and heart failure.
Histone acetylation has been implicated in relaxing chro-
atin and globally exposing genes for transcription. Re-
oval of acetyl groups is presumed to result in chromatin
ompaction, making some promoters inaccessible for tran-
criptional activation. Inhibition of HDAC activity, and
articularly class I HDACs, has ironically been associated
ith attenuation of cardiac growth and hypertrophy in vitro
nd in vivo. The exact mechanism(s) by which HDAC
nhibition attenuates hypertrophy is not entirely known.
lass II HDACs are antihypertrophic, whereas class I
DACs may stimulate cardiac growth and sarcomeric
enes. Selective HDAC or HAT inhibitors are being ac-
ively developed and are in trials for the treatment of cancer.
s such, identification of the specific HATs or HDACs
ssociated with hypertrophy-responsive transcription fac-
ors, such as GATA-4, DTEF-1, or Sp1/3, (1) may allow for
he identification of the transcriptional mechanisms of
athologic hypertrophy and (2) may allow for the use of
soform-specific HAT/HDAC inhibitors to target pathologic
ypertrophy and contractile dysfunction of the heart.
We thank Leonard Moon for assistance with the manuscript
nd figures.
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r Robert C. Robbins (Stanford, Calif). You went through it very
uickly, but this is a tour de force; technically it is a very difficult
odel and you are to be congratulated for getting the animals
hrough this. Also impressive is the sophisticated use of molecular
enetics that you used here to help answer important questions.
ertainly heart failure is an important public health issue. Finally,
he experimental therapeutic approach to try to identify potential
argets for developing small molecules or other strategies to treat
eart failure is impressive.
I have just a couple of comments and questions for you.
GATA-4 and NKx2.5 are things that we are looking at as
mbryonic stem cells differentiate into cardiac myocytes. I thought
t was interesting that you targeted these particular transcription
actors. You mentioned the isoform shift of cardiac myosin in your
anuscript, and a lot of work has been done by Jeff Robbins in this
rea. I would like to note that you mentioned cardiac myosin.
ecause it is so important in allograft rejection and autoimmune
isease, can you comment on what you found with cardiac myosin
pecifically?
Dr Azakie. We used the MF20 antibody, which selects for
yosins. The purpose of looking at changes in sarcomeric gene
xpression was to show that, in fact, there was biochemical hy-
ertrophy. We did not look specifically for different myosin iso-
orms. What we wanted to show is that despite no change in DNA
ontent, there was an upregulation in myosin proteins. The purpose
n evaluating cTnT expression was to show that, in fact, an
mbryonic gene expression pattern induced a marker of the devel-
pment of pathologic hypertrophy. We also looked at serum brain
atriuretic peptide and found that it was significantly upregulated
n shunted animals. We did not look at isoform-specific expression
f different myosins.
Dr Robbins. You hit on other things that I was going to ask
ou about. Have you thought about using microarrays? I’ve been
mpressed that often this is a fishing expedition, but it can often
irect you to other things. You have done it the old-fashioned way.
ou have picked a couple of things and gone after them in the
lassic sense. Have you thought about using microarrays to look
or other targets? We have recently discovered a gene termed
PLN in heart failure patients who had ventricular assist devices.
wonder whether you could get more targets if you would con-
idered using microarray techniques.
Dr Azakie. We thought about using microarrays, but there are
o good ovine arrays available now. They are in preparation. The
ain issue that my colleagues and collaborators have had with that
pproach is that it does not always necessarily provide a mecha-
istic answer toward the switch to a hypertrophic program.
I think the main message here resided in the posttranslational
odifications and the functional assays that we performed. Neo-
atal ovine cardiomyocytes were cultured and cotransfected with
ardiac promoters and expression constructs that encoded different
ranscription factors. We found that TEF-1 and Sp1 were transcrip-
ional activators, whereas Sp3 was a repressor. GATA-4 and
KX2.5 were selected because they are very well-known tran-
criptional activators that are important for development and really
et a standard.
ember 2006
The next level was to look at the posttranslational modifications
that occurred, and specifically acetylation and ADP-ribosylation.
Cardiac histone acetylation has been implicated in pathologic
cardiac growth, and currently there are HDAC inhibitors that are
being developed for use in cancer therapy in ongoing clinical trials.
Class I HDAC inhibitors have recently been shown to suppress
the development of hypertrophy in a rodent model where the aorta
was banded or angiotensin was infused.
The answer to the question, in short, is that we were interested
in trying to determine the mechanisms by which the hypertrophic
transcriptional program was initiated and that is why we did not do
microarrays.
Dr Robbins. You mentioned in your manuscript about models
of pressure overload to the left ventricle that are much easier to do,
such as constriction of the ascending aorta in transgenic mice. This
is very specific to the previous point. You are to be congratulated
for focusing in and testing the specific hypothesis, but I wonder
whether this is too narrow an area. I understand that your interest
is in surgery for congenital heart disease, but how do you think that
these data would translate into more generalizable models of
ischemic cardiomyopathy or rapid pacing, other models of heart
failure?
Finally, how do you choose the next step? Do you try to block
Sp1 or do you try to increase Sp3 in pharmacologic methods?
Dr Azakie. This model is interesting because it mimics certain
congenital heart defects, but the model can be tailored to produce
pressure loading of the left ventricle.
With regard to other more common causes of congestive heart
failure, I think that our hypothesis, and the hypotheses of others, is
that although there are different types of biomechanical stressors,
like pressure overload, volume overload, and ischemia-reperfusion
injury, which stimulate different intracellular signaling pathways,
we believe that ultimately there is a transcriptional reprogramming
that develops within the nucleus of the cardiac myocyte and so
really represents a final common pathway.
Finally, with regard to the next step for this line of research,
I think our plan will be to use selective class I HDAC inhibitors
as well as selective HAT inhibitors in determining whether or
not those agents can either reverse the (volume-loaded) hyper-
trophic process or prevent the development of heart failure.
Dr Ludwig K. von Segesser (Lausanne, Switzerland). Did
you consider going the other way around and closing the shunt
to see how your molecular patterns precede or follow the
morphology?
Dr Azakie. That’s a very good question. We did not do that.
Maybe doing that would be an interesting way to support the
mechanisms that we are trying to infer here. It’s a very good
question and good suggestion. Thank you.
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Dppendix E1: Chromatin Immunoprecipitation
upplement
ethod: Chromatin Immunoprecipitation (ChIP)
ll ChIP assays were performed on the basis of the protocols of
he chromatin immunoprecipitation assay kit (Upstate, Lake
lacid, NY) [Azakie, 2005—AJP]. Five micrograms of primary
ntibody against DTEF-1, GATA-4, MEF2, NKX2.5, Sp1, Sp3,
ARP, or PAR was added to a 500 L chromatin sample for the
mmunoprecipitation reaction. ChIP dilution buffer and preim-
une rabbit serum were used as controls for nonspecific interac-
ions and DNA contamination. Anti--actin and anti-cTnT anti-
odies were used as negative controls.
271.e1 The Journal of Thoracic and Cardiovascular Surgery ● Dolymerase Chain Reaction
fter DNA purification, samples were subjected to polymerase
hain reaction with primers designed for the chick heart cTnT
romoter (cTnT-268) as follows: upper primer: 5=GCTGGCTG-
CTTGTGTCA-3=; lower primer: 5=-CTTGGGGGGCAGAG-
CTTT-3=.
The primers used for polymerase chain reaction were designed
y a primer analysis software (Oligo 6.8; Molecular Biology
nsights, Inc, Cascade, Colo). The amplified polymerase chain
eaction product is 265 bp.ecember 2006
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Figure E1. Shunted hearts showed 4-chamber cardiomegaly.
Figure E2. Immunohistochemistry of sheep myocardium double-stained with MF20 (red) antibody and Sp1 antibody
(green immunofluorescence).
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Digure E3. Immunohistochemistry of sheep myocardium double-
tained with MF20 (red) antibody and Sp3 antibody (green
mmunofluorescence).F
v
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n
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r
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aigure E4. Immunohistochemistry of sheep myocardium double-
tained with MF20 (red) antibody and DTEF-1 antibody (green
mmunofluorescence).
271.e3 The Journal of Thoracic and Cardiovascular Surgery ● Digure E5. Transcriptional complexes bind the cTnT promoter in
ivo. Polymerase chain reaction using primers specific for cTnT
romoter on DNA purified after chromatin immunoprecipitation.
fter cross-linking and sonication, chromatin complexes from
eonatal sheep heart nuclear preparations were purified. Chro-
atin was incubated with antibodies to DTEF-1, MEF2, GATA-4,
kx2.5, Sp1, Sp3, poly-ADP-ribose polymerase (PARP), poly-ADP-
ibose (PAR), -actin, cTnT, and preimmune serum. Separation of
mmune complexes by elution from protein A/G/agarose beads
as followed by reversal of protein-DNA crosslinks and DNA
urification. Lane A depicts chromatin input DNA plus antibody.
anes A-E include the ChIP “output” DNA for polymerase chain
eactions. Immunoprecipitation of chromatin preparations was
erformed with antibodies listed on the left-sided column. Lane F
ontains ChIP buffer as the “DNA source.” Lane G contains the
ontrol, “input DNA” to verify the quality of nuclear preparations.
, Output DNA; b, input DNA; c, polymerase chain reaction buffer
nd primers.ecember 2006
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Figure E6. Histone acetyl transferase (HAT) activity associated with immunoprecipitated Sp3 is upregulated during
pathologic cardiac hypertrophy.0
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Figure E7. Histone deacetylase activity associated with immunoprecipitated Sp3 is decreased during pathologic
hypertrophy.
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